105 results on '"LINDE, CECILIA"'
Search Results
2. Benefit of cardiac resynchronization therapy among older patients: A patient-level meta-analysis
3. Will the results from the AdaptResponse trial boost CRT use?
4. PO-02-027 RELATIONSHIP BETWEEN SEX, BODY SIZE, AND CRT BENEFIT: A PATIENT LEVEL META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
5. Association Of Comorbidities With Clinical Outcomes Of Cardiac Resynchronization Therapy: A Meta-analysis Of Patient-level Data From Eight Major Clinical Trials
6. IRON DEFICIENCY IN HEART FAILURE: SCREENING, PREVALENCE, INCIDENCE, IRON NEED, AND OUTCOMES
7. Outcomes of Conduction System Pacing for Cardiac Resynchronization Therapy in Patients with Heart Failure: A Multicenter Experience
8. Association of left ventricular remodeling with cardiac resynchronization therapy outcomes
9. CI-569-02 CONDUCTION SYSTEM PACING FOR CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH HEART FAILURE
10. PO-628-08 RESPONSE TO CRT IS DIFFERENT IN PATIENTS WITH IVCD COMPARED TO RBBB: A PATIENT LEVEL META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
11. PO-688-07 IMPACT OF BASELINE PR INTERVAL ON RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF FIVE RANDOMIZED TRIALS
12. Identifying risk of adverse outcomes in COVID-19 patients via artificial intelligence–powered analysis of 12-lead intake electrocardiogram
13. The importance of early evaluation after cardiac resynchronization therapy to redefine response: Pooled individual patient analysis from 5 prospective studies
14. B-PO01-094 ARTIFICIAL INTELLIGENCE (AI) CAN IDENTIFY RISK OF DEATH IN COVID-19 PATIENTS USING 12-LEAD INTAKE ELECTROCARDIOGRAM (ECG) ALONE
15. Redefining the Classifications of Response to Cardiac Resynchronization Therapy
16. Importance of Systematic Right Ventricular Assessment in Cardiac Resynchronization Therapy Candidates: A Machine Learning Approach
17. Prognostic utility of the assessment of diastolic function in patients undergoing cardiac resynchronization therapy
18. Identifying Risk of Adverse Outcomes in COVID-19 Patients via Artificial Intelligence-Powered Analysis of 12-Lead Intake Electrocardiogram.
19. Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery disease—A randomized controlled trial
20. Metabolomic Profile in HFpEF vs HFrEF Patients
21. Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria
22. Increased iron absorption in patients with chronic heart failure and iron deficiency
23. Future research prioritization in cardiac resynchronization therapy
24. PREDICTORS OF NON-USE OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS FOR PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH IN HEART FAILURE
25. Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)
26. Resultados en España de la encuesta de la Sociedad Europea de Cardiología sobre terapia de resincronización cardiaca (CRT-Survey II)
27. The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France
28. Sex-Related Procedural Aspects and Complications in CRT Survey II
29. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum
30. Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study
31. Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome
32. Corrigendum to “Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study” [Int. J. Cardiol. 226 (2017) 65–70]
33. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction
34. Indications for Cardiac Resynchronization Therapy
35. Cardiomyopathy and Left Bundle Branch Block
36. The Impact of the PR Interval in Patients Receiving Cardiac Resynchronization Therapy
37. The burden of proof: The current state of atrial fibrillation prevention and treatment trials
38. HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1
39. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization
40. HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin
41. Cardiac Resynchronization Therapy Follow-up
42. Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study
43. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
44. Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
45. Biventricular Stimulation
46. EFFECT OF SPINAL CORD STIMULATION ON CARDIAC SYMPATHETIC NERVE ACTIVITY IN PATIENTS WITH HEART FAILURE
47. Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure
48. Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study
49. 0370: The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study
50. Cardiac Resynchronization Therapy Follow-up
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.